sintilimab + sapropterin dihydrochloride

This combination consists of **sintilimab**, a fully human IgG4 monoclonal antibody that targets and blocks programmed cell death protein 1 (PD-1), enhancing T-cell anti-tumor activity, and **sapropterin dihydrochloride**, a synthetic form of tetrahydrobiopterin (BH4) that acts as a cofactor for phenylalanine hydroxylase and is primarily used to treat phenylketonuria. Sintilimab has been primarily explored as an immunotherapy for cancers such as classical Hodgkin lymphoma and non-small cell lung cancer, whereas sapropterin dihydrochloride is approved for metabolic disorders, not cancer. There is no evidence from available sources that this specific combination is approved or studied as a single product or investigational agent.

Brand names

Tyvyt

Other names

Anti-PD-1 monoclonal antibody IBI308Anti-PD1 monoclonal antibody IBI308Anti-PD 1 monoclonal antibody IBI308